Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Remington

Showing results (31-40 of 410) with videos related to

Pageof 41
Sort By:
Evidence-Based Mental Health|August 16, 2002
Review: amisulpride is effective and safe for schizophreniaGary Remington, Shitij Kapur
Schizophrenia Bulletin|July 23, 2008
Negative symptoms in schizophrenia: avolition and Occam's razorGeorge Foussias, Gary Remington
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 8, 2010
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-makingGeorge Foussias, Gary Remington
Annals of the Academy of Medicine, Singapore|February 24, 2015
Schizophrenia as a lifelong illness: implications for careJimmy Lee, Gary Remington
Expert Opinion on Pharmacotherapy|December 21, 2013
Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trialsNaren P Rao, Gary Remington
Schizophrenia Research|December 6, 2018
Clozapine-induced myocarditis in Canada: Evidence from spontaneous reportsNicholas H Neufeld, Gary Remington
Expert Opinion on Investigational Drugs|May 4, 2013
Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trialsNaren P Rao, Gary Remington
Expert Opinion on Emerging Drugs|July 14, 2015
Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trialsJonathan Tomas Lockwood, Gary Remington
Expert Review of Neurotherapeutics|April 8, 2011
Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatmentGary Remington, Ofer Agid, George Foussias
The Journal of Clinical Psychiatry|September 18, 2009
Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover studySanjeev Sockalingam, Chekkera Shammi, Gary Remington
Pageof 41

Showing results (31-40 of 410) with videos related to

Sort By:
Pageof 41
Evidence-Based Mental Health|August 16, 2002
Review: amisulpride is effective and safe for schizophreniaGary Remington, Shitij Kapur
Schizophrenia Bulletin|July 23, 2008
Negative symptoms in schizophrenia: avolition and Occam's razorGeorge Foussias, Gary Remington
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|April 8, 2010
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-makingGeorge Foussias, Gary Remington
Annals of the Academy of Medicine, Singapore|February 24, 2015
Schizophrenia as a lifelong illness: implications for careJimmy Lee, Gary Remington
Expert Opinion on Pharmacotherapy|December 21, 2013
Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trialsNaren P Rao, Gary Remington
Schizophrenia Research|December 6, 2018
Clozapine-induced myocarditis in Canada: Evidence from spontaneous reportsNicholas H Neufeld, Gary Remington
Expert Opinion on Investigational Drugs|May 4, 2013
Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trialsNaren P Rao, Gary Remington
Expert Opinion on Emerging Drugs|July 14, 2015
Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trialsJonathan Tomas Lockwood, Gary Remington
Expert Review of Neurotherapeutics|April 8, 2011
Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatmentGary Remington, Ofer Agid, George Foussias
The Journal of Clinical Psychiatry|September 18, 2009
Treatment of clozapine-induced hypersalivation with ipratropium bromide: a randomized, double-blind, placebo-controlled crossover studySanjeev Sockalingam, Chekkera Shammi, Gary Remington
Pageof 41